Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Diabetes & Endocrinology

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Surgery

Show all topics

DOI

10.1016/s2213-8587(17)30308-x

Other Formats

PDF